Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes

doi:10.1016/j.diabres.2021.109022

Diabetes Research and Clinical Practice

Volume 179, September 2021, 109022

https://doi.org/10.1016/j.diabres.2021.109022 Get rights and content

Abstract

In patients with autoimmune diabetes no significant differences were observed in glucose control, expressed as time in range evaluated by continuous glucose monitoring comparing the 3 days after Sars-Cov2 vaccine with the 14 days preceding the vaccine.

Keywords

Sars-Cov-2

Vaccination

Glucose control

Diabetes

CGM

Cited by (0)

View Abstract

Diabetes Research and Clinical Practice

Brief ReportShort-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes

Abstract

Keywords

Brief Report
Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes